ClinicalTrials.gg
Not yet recruitingNCT07946328Updated Nov 18, 2026

Home-Based Transitional Cardiac Rehabilitation Trial With a Partially Randomized Patient Preference Design

An interventional study of Hybrid cardiac rehabilitation (hospital-to-home transition) and Standard center-based cardiac rehabilitation:as in Arm 2. in Cardiovascular Diseases and Post-cardiac Surgery, sponsored by Cheng-Hsin General Hospital. Not yet recruiting. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Cheng-Hsin General Hospital · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

This is a prospective, single-center, non-inferiority trial comparing a hospital-to-home transitional cardiac rehabilitation model with standard hospital-based cardiac rehabilitation in low-risk patients after cardiac surgery in Taiwan. Because patients' post-discharge scheduling constraints and treatment preferences make full randomization difficult to sustain in practice, the trial uses a Partially Randomized Patient Preference (PRPP) design: patients without a strong preference are randomized 1:1 to the two programs and form the randomized core cohort used for the primary confirmatory analysis, while patients with a clear, pre-specified preference are assigned accordingly and followed descriptively as a preference cohort. The primary hypothesis is that the hospital-to-home model is non-inferior to hospital-based rehabilitation in improving peak oxygen uptake (Peak VO2) after 8 weeks. A pre-specified key secondary hypothesis, based on an exploratory finding from the investigators' completed pilot study, is that the hospital-to-home model results in significantly lower 6-month outpatient medical costs. The trial does not include a no-treatment control arm; assay sensitivity is instead supported by the extensive existing evidence base for cardiac rehabilitation versus no treatment and for home-based versus center-based cardiac rehabilitation equivalence, following the constancy assumption described in ICH E10.

Read the detailed description

Rationale: A completed single-center pilot study (Cheng Hsin General Hospital institutional research grant, FY112) enrolled 30 patients (15 per arm, 4 withdrawals) and found a directional, exploratory signal of non-inferiority for the hospital-to-home model on Peak VO2, and a significant reduction in 6-month outpatient medical costs favoring the hospital-to-home arm. However, the pilot's original sample size was calculated using a two-tailed paired-sample t-test, which is not the correct method for a parallel-group non-inferiority design, so its non-inferiority conclusion was exploratory only. This confirmatory trial re-estimates the required sample size using the pilot's observed variance (ANCOVA-adjusted residual SD = 2.71 ml/min/kg) and the correct non-inferiority formula, and adopts a Partially Randomized Patient Preference (PRPP) design to address the real-world constraint that many post-discharge patients have strong scheduling or logistical preferences between an in-hospital and a home-based program.

Design: Prospective, parallel-group, non-inferiority trial with PRPP allocation. Patients without a strong preference (operationally defined as absence of a specific, identifiable scheduling, transportation, or technology-related constraint) are randomized 1:1 in permuted blocks to the hospital-to-home transitional model or hospital-based cardiac rehabilitation, forming the randomized core cohort (planned n=29 per arm, 58 total) that constitutes the intention-to-treat population for the primary confirmatory non-inferiority analysis. Patients with a clear, investigator-confirmed preference are assigned to their preferred program and followed as a preference cohort (planned n≈40) analyzed descriptively; their baseline characteristics are compared with the randomized core cohort to characterize potential selection effects, but they do not contribute to the primary confirmatory hypothesis test. Assuming approximately 60% of screened patients accept randomization (a planning assumption to be re-examined at the interim analysis), the overall enrollment target is 98 participants.

No-treatment control arm: The trial does not include a usual-care/no-rehabilitation control arm. The investigators considered a three-arm design to formally establish assay sensitivity but did not adopt it because (a) the effect of cardiac rehabilitation versus no treatment is already well established by a large existing evidence base, including the Cochrane meta-analyses cited in the 2026 ESC Guidelines on Cardiac Rehabilitation (85 RCTs / 23,430 patients in coronary artery disease; 60 RCTs / 8,728 patients in heart failure); (b) the equivalence of home-based and center-based cardiac rehabilitation has similarly been established at the meta-analytic level by the 2023 Cochrane review (24 RCTs, 3,046 patients); (c) adding a no-treatment arm would raise the enrollment target from 58 to approximately 134 in the randomized core cohort, which is not feasible for a single center; and (d) published hybrid cardiac rehabilitation non-inferiority/equivalence trials (iATTEND, HYCARET, and a French single-center trial) have similarly used two active comparator arms without a no-treatment control. This design relies on the ICH E10 constancy assumption rather than re-establishing assay sensitivity with concurrent trial data.

Outcome hierarchy: Given the number of secondary endpoints assessed in the pilot without multiplicity correction, this trial pre-specifies a hierarchical (fixed-sequence) gatekeeping procedure to control the family-wise type I error rate: Gate 1 tests the primary non-inferiority hypothesis on Peak VO2; Gate 2, tested only if Gate 1 is met, formally tests the pre-specified key secondary hypothesis on 6-month outpatient medical cost; Gate 3 outcomes (quality of life/QALY, medication adherence, secondary CPET indices, pulmonary function) are analyzed and reported descriptively as pre-specified but exploratory, without formal multiplicity control, and are entered under Other Pre-specified Outcome Measures below rather than Secondary Outcome Measures.

Missing data: Primary and secondary efficacy outcomes with missing values will be handled by multiple imputation (MICE, ≥20 imputations, pooled per Rubin's rules), with complete-case analysis as a sensitivity analysis. An interim analysis is planned at 50% enrollment for safety monitoring by an independent Data Safety Monitoring Board (DSMB); no interim efficacy testing is performed, so no alpha-spending adjustment is required. The interim analysis will also re-examine the actual randomization-acceptance rate against the 60% planning assumption and adjust the recruitment period or target if needed.

02

Conditions studied

  • Cardiovascular Diseases
  • Post-cardiac Surgery

Keywords

  • Cardiac Rehabilitation
  • Home-Based Cardiac Rehabilitation
  • Hybrid Cardiac Rehabilitation
  • Telerehabilitation
  • Transitional Care
  • Non-Inferiority Trial
  • Partially Randomized Patient Preference
  • PRPP
  • Peak Oxygen Uptake
  • Cost-Utility Analysis
03

In context

Cardiovascular Diseases

5,374 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 151 is above the median of 100 across 3,085 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Cheng-Hsin General Hospital is the lead sponsor of 24 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Post-cardiac-surgery patients at the study hospital
  • Age 20-75 years
  • Low cardiovascular risk (AHA 2013 exercise training risk stratification, Class B), clinically stable
  • Able to self-monitor exercise intensity

Exclusion criteria

Exclusion Criteria

  • High risk of sudden cardiac death
  • Sustained atrial fibrillation or non-sustained ventricular tachycardia within the preceding 6 months
  • Implanted cardioverter-defibrillator (ICD)
  • Unable to independently operate the communication/exercise software or devices required for the home-based program
  • Declines to undergo study testing
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
151 participants (estimated)

Study arms

  • Experimental
    Hybrid cardiac rehabilitation (Experimental)

    Description:Weeks 1-2: 4 supervised hospital sessions (twice weekly). End of week 2: risk reassessment (AACVPR algorithm; patients with high-risk features do not transition to home) and teaching of home resistance exercise. Weeks 3-8: home aerobic exercise at least 3 times per week and elastic-band resistance exercise at least 2 times per week; remote 30-second ECG at rest daily and after each exercise session; exercise log; weekly telephone call; two standardized text messages per week; return visit at week 4. Participants choose this arm.

    Behavioral: Hybrid cardiac rehabilitation (hospital-to-home transition)

  • Active comparator
    Standard center-based cardiac rehabilitation (Active Comparator)

    Description:Two supervised hospital sessions per week for 8 weeks (16 sessions), plus weekly verbal encouragement to exercise on their own and a home exercise log. Exercise prescription follows the hospital routine and is made in the same way as in the hybrid arm. Participants choose this arm.

    Behavioral: Standard center-based cardiac rehabilitation:as in Arm 2.

Interventions

  • BehavioralHybrid cardiac rehabilitation (hospital-to-home transition)

    Hybrid cardiac rehabilitation (hospital-to-home transition):as in Arm 1; aerobic intensity is based on the anaerobic-threshold heart rate from baseline CPET when available, otherwise moderate intensity (RPE 12-13); resistance exercise uses elastic bands (4-8 exercises, RPE 11-13) with sternal precautions; intensity at home does not exceed the hospital sessions; upper-limb movements at home are added only after individual confirmation by the therapist.

  • BehavioralStandard center-based cardiac rehabilitation:as in Arm 2.

    Standard center-based cardiac rehabilitation:as in Arm 2.

06

What researchers measure

Primary outcomes

  1. Change in Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing

    Description:VO2peak (mL/kg/min) is the highest 30-second average oxygen uptake during a symptom-limited bicycle ramp cardiopulmonary exercise test with breath-by-breath gas analysis. Change = week 8 value minus week 0 value. Non-inferiority margin: 1.5 mL/kg/min.

    Time frame: Baseline (Week 0) and Week 8

Secondary outcomes

  1. Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing at 6 Months After Week 8

    Description:Key secondary outcome. VO2peak (mL/kg/min) measured as for the primary outcome. Tested in a fixed sequence only if non-inferiority is shown for the primary outcome.

    Time frame: 6 months after week 8

  2. Number of Attended Supervised Exercise Sessions, From Hospital Attendance Records

    Description:Count of supervised hospital sessions attended per participant (prescribed: 4 in the hybrid arm, 16 in the standard arm).

    Time frame: Weeks 1-8.

  3. Number of Home Exercise Sessions per Week, Recorded in the Home Exercise Log

    Description:Mean number of self-reported home exercise sessions per week (aerobic and resistance), from the participant's home exercise log.

    Time frame: Weeks 1-8.

  4. Number of Participants Who Attend at Least 80% of Prescribed Supervised Sessions, From Hospital Attendance Records

    Description:Participants attending at least 80% of the supervised sessions prescribed for their arm.

    Time frame: Week 8.

  5. Health Utility Measured by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Index Score Using the Taiwan Value Set

    Description:The EQ-5D-5L describes health in 5 dimensions with 5 levels each; responses are converted to an index score with the Taiwan value set (Lin et al., PLoS One 2018). Index range -1.0259 to 1; 1 = full health; higher scores indicate better health.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  6. Self-Rated Health Measured by the EuroQol Visual Analogue Scale (EQ VAS)

    Description:EQ VAS ranges from 0 (worst imaginable health) to 100 (best imaginable health); higher scores indicate better health.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  7. Six-Minute Walk Distance Measured by the 6-Minute Walk Test

    Description:Distance walked in 6 minutes (meters).

    Time frame: Baseline (week 0) and week 8

  8. Patient Satisfaction Measured by the Client Satisfaction Questionnaire-8 (CSQ-8) Total Score

    Description:8 items each scored 1 to 4; total score ranges from 8 to 32; higher scores indicate greater satisfaction.

    Time frame: Week 8 and 6 months after week 8

Other outcomes

  1. Number of Outpatient Visits, Excluding Cardiac Rehabilitation Sessions, From Hospital Records and National Health Insurance Data

    Count of outpatient visits per participant; cardiac rehabilitation sessions are excluded.

    Time frame: From week 8 through 6 months after week 8

  2. Number of Emergency Department Visits, From Hospital Records and National Health Insurance Data

    Count of emergency department visits per participant.

    Time frame: From week 8 through 6 months after week 8

  3. Number of Hospital Admissions, From Hospital Records and National Health Insurance Data

    Count of hospital admissions per participant.

    Time frame: From week 8 through 6 months after week 8

  4. Total Length of Hospital Stay, From Hospital Records and National Health Insurance Data

    Total inpatient days per participant.

    Time frame: From week 8 through 6 months after week 8

  5. Outpatient and Emergency Department Medical Expenditure, Excluding Cardiac Rehabilitation-Related Charges

    Total outpatient and emergency department medical expenditure per participant in New Taiwan Dollars (NTD), from hospital billing records and National Health Insurance data.

    Time frame: From week 8 through 6 months after week 8

  6. Inpatient Medical Expenditure

    Total inpatient medical expenditure per participant in NTD, from hospital billing records and National Health Insurance data.

    Time frame: From week 8 through 6 months after week 8

  7. Participant Time Spent on the Rehabilitation Program, Measured by a Study-Specific Time-Cost Questionnaire

    Total hours spent on travel to and from the hospital and on rehabilitation sessions (supervised and home-based) per participant.

    Time frame: Weeks 1-8

  8. Medication Adherence Measured by the 8-Item Morisky Medication Adherence Scale (MMAS-8)

    Total score ranges from 0 to 8; higher scores indicate better adherence.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  9. Number of Participants Reporting Current Tobacco Use, Assessed by Self-Report Questionnaire

    Participants reporting any tobacco use in the past 30 days

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  10. Muscle Mass Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)

    Muscle mass in kilograms.

    Time frame: Baseline (week 0) and week 8

  11. Body Fat Percentage Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)

    Body fat as a percentage of body weight.

    Time frame: Baseline (week 0) and week 8

  12. Forced Vital Capacity (FVC) Measured by Spirometry

    FVC in liters.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  13. Forced Expiratory Volume in 1 Second (FEV1) Measured by Spirometry

    FEV1 in liters.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  14. Ratio of FEV1 to FVC (FEV1/FVC) Measured by Spirometry

    FEV1/FVC expressed as a percentage.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  15. Minute Ventilation to Carbon Dioxide Output Slope (VE/VCO2 Slope) Measured by Cardiopulmonary Exercise Testing

    Slope of the linear relationship between minute ventilation and carbon dioxide output during exercise (unitless); lower values indicate better ventilatory efficiency.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  16. Oxygen Uptake Efficiency Slope (OUES) Measured by Cardiopulmonary Exercise Testing

    Slope of oxygen uptake (mL/min) against the log10 of minute ventilation (L/min); higher values indicate better efficiency.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  17. Oxygen Uptake at the First Ventilatory Threshold (VO2 at VT1) Measured by Cardiopulmonary Exercise Testing

    VO2 at the first ventilatory threshold in mL/kg/min.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  18. Heart Rate Recovery at 1 Minute (HRR1) After Cardiopulmonary Exercise Testing

    Peak heart rate minus heart rate 1 minute into recovery, in beats per minute; higher values indicate better recovery.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  19. Heart Disease-Specific Quality of Life Measured by the MacNew Heart Disease Health-Related Quality of Life Questionnaire Global Score

    27 items; global score ranges from 1 to 7; higher scores indicate better health-related quality of life.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  20. Depressive Symptoms Measured by the Patient Health Questionnaire-9 (PHQ-9) Total Score

    Total score ranges from 0 to 27; higher scores indicate more severe depressive symptoms.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  21. Anxiety Symptoms Measured by the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score

    Total score ranges from 0 to 21; higher scores indicate more severe anxiety symptoms.

    Time frame: Baseline (week 0), week 8, and 6 months after week 8

  22. Number of Participants With Adverse Events During Exercise Testing, Supervised Training or Home Exercise

    Adverse events include cardiovascular events (e.g., arrhythmia requiring intervention, angina, syncope, abnormal blood pressure response, myocardial infarction, stroke, death), musculoskeletal injury and sternal wound complications, recorded by therapists, the remote ECG review, the exercise log and weekly telephone calls.

    Time frame: From baseline (week 0) through 6 months after week 8 (approximately 8 months)

  23. Number of Participants Who Discontinue the Intervention

    Participants who stop the assigned intervention for any reason; reasons are reported.

    Time frame: Weeks 1-8

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Feb 2028, 13 months later.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 13 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Feb 28, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946328
Lead sponsor
Cheng-Hsin General Hospital
Responsible party
Yu-Shan Lin (Chief Physical Therapist, Cheng-Hsin General Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

SHENG-CHI Lo, BS. PT.
Contact
fy10940619@gmail.com
+886-02-28264400 EXT 3459
Yu-Shan Lin, PT, MSc, CRFC
Contact
itsyushanlin@gmail.com
+886-02-28264400 EXT 3459
Yu-Shan Lin, PT, MSc, CRFC
principal investigator · Chief Physical Therapist, Cheng Hsin General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion